All In Biotech

Drug Trial Radar · NCT07180511

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

A Multicenter, Randomized, Parallel, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Moderate to Severe Atopic Dermatitis.

Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

460

Planned (sponsor's estimate)

Start

Mar 12, 2025

Primary completion

May 18, 2027

Study completion Jul 19, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • 10mg QY201 Placebo tabletDrug

    10mg QY201 Placebo tablet

  • 20mg QY201 Placebo tabletDrug

    20mg QY201 Placebo tablet

  • 10mg QY201 tabletDrug

    10mg QY201 tablet

  • 20mg QY201 tabletDrug

    20mg QY201 tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects who achieved EASI-75 at week 16 of treatment.Time frame: At week 16 of treatment
  2. The proportion of subjects who achieved vIGA-AD 0/1 with a reduction of ≥2 points from baseline at week 16 of treatment.Time frame: At week 16 of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • EnitiateBioPharma

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.